Skip to main content
Top
Published in: Dermatology and Therapy 2/2022

Open Access 01-02-2022 | Probiotics | Original Research

Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement

Authors: Fabio Rinaldi, Laura Marotta, Antonio Mascolo, Angela Amoruso, Marco Pane, Giammaria Giuliani, Daniela Pinto

Published in: Dermatology and Therapy | Issue 2/2022

Login to get access

Abstract

Introduction

Treatments other than topical and systemic antibiotics are needed to restore the dysbiosis correlated with acne onset and evolution. In this view, probiotics and botanical extracts could represent a valid adjunctive therapeutic approach. The purpose of this study was to test the efficacy of a dietary supplement containing probiotics (Bifidobacterium breve BR03 DSM 16604, Lacticaseibacillus casei LC03 DSM 27537, and Ligilactobacillus salivarius LS03 DSM 22776) and botanical extract (lupeol from Solanum melongena L. and Echinacea extract) in subjects with mild to moderate acne over an 8-week study period.

Methods

Monocentric, randomized, double-blind, four-arm, placebo-controlled clinical study involving 114 subjects.

Results

A significant (p < 0.05) effect on the number of superficial inflammatory lesions was reported over the study period in the subjects taking the study agent (group II) (−56.67%), the botanical extracts (group III) (−40.00%), and the probiotics (group IV) (−38.89%) versus placebo (−10.00%). A significant (p < 0.05) decrease in mean desquamation score, sebum secretion rate, and porphyrin mean count versus baseline was also reported, and the effect was most evident for group II. The analysis of log relative abundance after 4 and 8 weeks of treatment compared with baseline showed a significant (p < 0.01) decrease in Cutibacterium acnes and S. aureus, along with a contextually and significant (p < 0.05) increase in Staphylococcus epidermidis, especially in group II. No significant changes were reported for group I.

Conclusion

The results from this study suggest that the administration of the dietary supplement under study was effective, safe, and well tolerated in subjects with mild to moderate acne and could represent a promising optional complement for the treatment of inflammatory acne as well as for control of acne-prone skin.
Literature
3.
go back to reference Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Investig Dermatol. 2014;134(6):1527–34.CrossRef Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Investig Dermatol. 2014;134(6):1527–34.CrossRef
4.
go back to reference Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB. Acne vulgaris in women: prevalence across the life span. J Womens Health. 2012;21(2):223–30.CrossRef Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB. Acne vulgaris in women: prevalence across the life span. J Womens Health. 2012;21(2):223–30.CrossRef
5.
go back to reference Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9.CrossRef Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9.CrossRef
6.
go back to reference Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermotol. 2001;2:135–41.CrossRef Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermotol. 2001;2:135–41.CrossRef
7.
go back to reference Kircik LH. Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol. 2014;13:s57-60.PubMed Kircik LH. Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol. 2014;13:s57-60.PubMed
8.
go back to reference Fabbrocini G, Cacciapuoiti S, Masarà A, Tedeschi A, Dall'Oglio F, Micali G. Linee Guida SIDEMAST per il trattamento dell'acne lieve e moderata. Pacini Editore Medicina eds. Pisa; 2015:1–12. Fabbrocini G, Cacciapuoiti S, Masarà A, Tedeschi A, Dall'Oglio F, Micali G. Linee Guida SIDEMAST per il trattamento dell'acne lieve e moderata. Pacini Editore Medicina eds. Pisa; 2015:1–12.
10.
go back to reference Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.CrossRef Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.CrossRef
11.
15.
go back to reference Yu Y, Dunaway S, Champer J, Kim J, Alikhan A. Changing our microbiome: probiotics in dermatology. Br J Dermatol. 2020;182(1):39–46.CrossRef Yu Y, Dunaway S, Champer J, Kim J, Alikhan A. Changing our microbiome: probiotics in dermatology. Br J Dermatol. 2020;182(1):39–46.CrossRef
16.
go back to reference Hacini-Rachinel F, Gheit H, Le Luduec J-B, Dif F, Nancey S, Kaiserlian D. Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS One. 2009;4:e4903.CrossRef Hacini-Rachinel F, Gheit H, Le Luduec J-B, Dif F, Nancey S, Kaiserlian D. Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS One. 2009;4:e4903.CrossRef
17.
go back to reference Muizzuddin N, Maher W, Sullivan M, Schnittger S, Mammone T. Physiological effect of a probiotic on skin. J Cosmet Sci. 2012;63(6):385–95.PubMed Muizzuddin N, Maher W, Sullivan M, Schnittger S, Mammone T. Physiological effect of a probiotic on skin. J Cosmet Sci. 2012;63(6):385–95.PubMed
18.
go back to reference Deidda F, Amoruso A, Nicola S, Graziano T, Pane M, Mogna L. New approach in acne therapy: a specific bacteriocin activity and a targeted anti IL-8 property in just 1 probiotic strain, the L. salivarius LS03. J Clin Gastroenterol. 2018;52 Suppl 1. In: Proceedings from the 9th probiotics, prebiotics and new foods, nutraceuticals and botanicals for nutrition & human and microbiota health meeting, held in Rome, Italy from September 10 to 12, 2017, pp S78–S81. https://doi.org/10.1097/MCG.0000000000001053 (PMID: 29782471). Deidda F, Amoruso A, Nicola S, Graziano T, Pane M, Mogna L. New approach in acne therapy: a specific bacteriocin activity and a targeted anti IL-8 property in just 1 probiotic strain, the L. salivarius LS03. J Clin Gastroenterol. 2018;52 Suppl 1. In: Proceedings from the 9th probiotics, prebiotics and new foods, nutraceuticals and botanicals for nutrition & human and microbiota health meeting, held in Rome, Italy from September 10 to 12, 2017, pp S78–S81. https://​doi.​org/​10.​1097/​MCG.​0000000000001053​ (PMID: 29782471).
19.
go back to reference Clark AK, Haas KN, Sivamani RK. Edible plants and their influence on the gut microbiome and acne. Int J Mol Sci. 2017;18(5):1070.CrossRef Clark AK, Haas KN, Sivamani RK. Edible plants and their influence on the gut microbiome and acne. Int J Mol Sci. 2017;18(5):1070.CrossRef
20.
go back to reference Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients’ experiences and perceptions. J Altern Complement Med. 2006;12(5):451–7.CrossRef Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients’ experiences and perceptions. J Altern Complement Med. 2006;12(5):451–7.CrossRef
23.
25.
go back to reference Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416–8.CrossRef Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416–8.CrossRef
32.
go back to reference Benyacoub J, Bosco N, Blanchard C, Demont A, Phillippe D, Castiel-Higounenc I. Immune modulation property of Lactobacillus paracasei NCC2461 (ST11) strain and impact on skin defenses. Benef Microbes. 2014;5:129–36.CrossRef Benyacoub J, Bosco N, Blanchard C, Demont A, Phillippe D, Castiel-Higounenc I. Immune modulation property of Lactobacillus paracasei NCC2461 (ST11) strain and impact on skin defenses. Benef Microbes. 2014;5:129–36.CrossRef
33.
go back to reference Gueniche A, Phillippe D, Bastien P, Reuteler G, Blum S, Castiel-Higounenc I. Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity. Benef Microbes. 2014;5:137–45.CrossRef Gueniche A, Phillippe D, Bastien P, Reuteler G, Blum S, Castiel-Higounenc I. Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity. Benef Microbes. 2014;5:137–45.CrossRef
34.
go back to reference Hashimoto K. Regulation of keratinocyte function by growth factors. J Dermatol Sci. 2000;24(Suppl. 1):S46–51.CrossRef Hashimoto K. Regulation of keratinocyte function by growth factors. J Dermatol Sci. 2000;24(Suppl. 1):S46–51.CrossRef
35.
go back to reference Pasonen-Seppanen S, Karvinen S, Torronen K, Hyttinen JM, Jokela T, Lammi MJ. EGF upregulates whereas TGF-beta downregulates the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J Investig Dermatol. 2003;120:1038–44.CrossRef Pasonen-Seppanen S, Karvinen S, Torronen K, Hyttinen JM, Jokela T, Lammi MJ. EGF upregulates whereas TGF-beta downregulates the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J Investig Dermatol. 2003;120:1038–44.CrossRef
36.
go back to reference Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013;17(2):114–22. https://doi.org/10.2310/7750.2012.12026 (PMID: 23582165).CrossRefPubMed Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013;17(2):114–22. https://​doi.​org/​10.​2310/​7750.​2012.​12026 (PMID: 23582165).CrossRefPubMed
37.
go back to reference Fabbrocini G, Cameli N, Lorenzi S, De Padova MP, Marasca C, Izzo R, Monfrecola G. A dietary supplement to reduce side effects of oral isotretinoin therapy in acne patients. G Ital Dermatol Venereol. 2014;149(4):441–5 (PMID: 25068233).PubMed Fabbrocini G, Cameli N, Lorenzi S, De Padova MP, Marasca C, Izzo R, Monfrecola G. A dietary supplement to reduce side effects of oral isotretinoin therapy in acne patients. G Ital Dermatol Venereol. 2014;149(4):441–5 (PMID: 25068233).PubMed
38.
go back to reference Silva DR, Sardi JD, de Souza Pitangui N, Roque SM, da Silva AC, Rosalen PL. Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Funct Foods. 2020;73:104080.CrossRef Silva DR, Sardi JD, de Souza Pitangui N, Roque SM, da Silva AC, Rosalen PL. Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Funct Foods. 2020;73:104080.CrossRef
39.
go back to reference Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell. Echinacea pallida (Nutt.) Nutt. Echinacea purpurea (L.) Moench: a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005;57:929–54.CrossRef Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell. Echinacea pallida (Nutt.) Nutt. Echinacea purpurea (L.) Moench: a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005;57:929–54.CrossRef
40.
go back to reference Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10:66–86.CrossRef Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10:66–86.CrossRef
41.
go back to reference Sharma M, Vohra S, Arnason JT, Hudson JB. Echinacea extracts contain significant and selective activities against human pathogenic bacteria. Pharm Biol. 2008;46:111–6.CrossRef Sharma M, Vohra S, Arnason JT, Hudson JB. Echinacea extracts contain significant and selective activities against human pathogenic bacteria. Pharm Biol. 2008;46:111–6.CrossRef
Metadata
Title
Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement
Authors
Fabio Rinaldi
Laura Marotta
Antonio Mascolo
Angela Amoruso
Marco Pane
Giammaria Giuliani
Daniela Pinto
Publication date
01-02-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-021-00664-z

Other articles of this Issue 2/2022

Dermatology and Therapy 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine